- Home
- RCUS vs HDL Comparison
RCUS vs HDL Comparison
Compare RCUS & HDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RCUS
- HDL
- Stock Information
- Founded
- RCUS 2015
- HDL 2016
- Country
- RCUS United States
- HDL Singapore
- Employees
- RCUS N/A
- HDL N/A
- Industry
- RCUS Biotechnology: Pharmaceutical Preparations
- HDL Restaurants
- Sector
- RCUS Health Care
- HDL Consumer Discretionary
- Exchange
- RCUS Nasdaq
- HDL Nasdaq
- Market Cap
- RCUS 1.2B
- HDL 1.1B
- IPO Year
- RCUS 2018
- HDL 2024
- Fundamental
- Price
- RCUS $13.90
- HDL $17.96
- Analyst Decision
- RCUS Buy
- HDL
- Analyst Count
- RCUS 7
- HDL 0
- Target Price
- RCUS $22.00
- HDL N/A
- AVG Volume (30 Days)
- RCUS 937.9K
- HDL 3.2K
- Earning Date
- RCUS 11-05-2025
- HDL 11-24-2025
- Dividend Yield
- RCUS N/A
- HDL N/A
- EPS Growth
- RCUS N/A
- HDL 197.81
- EPS
- RCUS N/A
- HDL 0.09
- Revenue
- RCUS $262,000,000.00
- HDL $805,433,000.00
- Revenue This Year
- RCUS N/A
- HDL $12.52
- Revenue Next Year
- RCUS N/A
- HDL $12.03
- P/E Ratio
- RCUS N/A
- HDL $193.08
- Revenue Growth
- RCUS 6.07
- HDL 9.65
- 52 Week Low
- RCUS $6.50
- HDL $15.54
- 52 Week High
- RCUS $18.98
- HDL $30.00
- Technical
- Relative Strength Index (RSI)
- RCUS 68.53
- HDL 40.28
- Support Level
- RCUS $12.89
- HDL $17.81
- Resistance Level
- RCUS $16.12
- HDL $18.79
- Average True Range (ATR)
- RCUS 0.73
- HDL 0.23
- MACD
- RCUS 0.07
- HDL -0.08
- Stochastic Oscillator
- RCUS 44.17
- HDL 10.28
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.
About HDL SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares
Super Hi International Holding Ltd is an investment holding company and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan. It mission is to become a global integrated restaurant group, build the world's Chinese cuisine brand, and promote Chinese culinary heritage world-wide.